Stanley Choy, Chief Financial Officer at Alphina Therapeutics

Stanley Choy

Chief Financial Officer at Alphina Therapeutics | Greenwich, Connecticut, United States

Profile last verified July 2026
Pharmaceuticals Verified Profile Greenwich, Connecticut, United States State University of New York College at Plattsburgh
Verified

Personal Email

***@yahoo.com

Personal • High Confidence

Phone Number

(203) ***-*374

United States • Phone

Free account · No credit card · 5 profiles/month

Stanley Choy Socials
Stanley Choy Work Experience

Co-Chairman, Board Member and Treasurer at BioCT - Connecting CT's Bioscience Community in January 2012 - Present

Co-founder and Partner at SHY Therapeutics, LLC in January 2014 - Present

Chief Financial and Business Officer at Qx Therapeutics Inc in January 2017 - Present

See more See less

Chief Operating and Business Officer at HLK Pharmacin LLC in January 2019 - Present

Chief Financial Officer at Alphina Therapeutics in September 2021 - Present

Vice President, Finance and Treasurer at Kolltan Pharmaceuticals, Inc. in January 2009 - January 2014

Chief Financial Officer at Edwards Angell Palmer & Dodge LLP in January 2006 - January 2009

Financial Controller at Shearman & Sterling LLP in January 2003 - January 2006

Finance Director at Pfizer Inc in January 1992 - January 2003

Tax Consultant at Arthur Andersen & Co. in January 1990 - January 1992

Senior Auditor at Arthur Andersen & Co. in January 1988 - January 1990

Stanley Choy Education

State University of New York College at Plattsburgh, BS, January 1980 to January 1984

Syracuse University - Martin J. Whitman School of Management, MBA, January 1986 to January 1988

Stanley Choy Skills
Due Diligence Accounting Tax Treasury Negotiation Strategic Planning Auditing Pharmaceutical Industry Strategy Investments Finance Mergers & Acquisitions Banking Management Leadership Financial Analysis Business Planning Executive Management Risk Management Financial Modeling Consulting Start-ups Business Strategy
About Stanley Choy’s Current Company
Alphina Therapeutics

At Alphina Therapeutics we are working to fulfill the promise of precision oncology — higher response rates for more patients. Our approach combines two cutting-edge scientific breakthroughs: First, our drug candidates use antibody-drug conjugate (ADC) technology to deliver potent NAMPT inhibitor payloads directly to the tumor. By disrupting cancer’s energy supply, these next-generation payloads are designed to kill both dividing and non-dividing tumor cells. Importantly, our therapies can be effective even when other ADCs, including Topo1-based treatments, no longer work. Second, we have developed a proprietary test that identifies the patients most likely to benefit from NAMPT inhibitors. Our goal is simple: match the right treatment with the right patient to achieve superior outcomes. Unlike most targeted treatments that help relatively few patients, ours could benefit more than 450,000 people each year in the U.S. alone. Our mission is to apply these breakthroughs to deliver smarter, more effective cancer therapies to the patients who urgently need them.

Discover more about Alphina Therapeutics
Stanley Choy’s Colleagues
Nick Galli

Nick Galli

New Haven, Connecticut, United States

CEO at Alphina Therapeutics

Chief Executive Officer at Alphina Therapeutics
(Oct 2024 – Present)

Marc Damelin

Marc Damelin

Greater Boston

Chief Scientific Officer at Alphina Therapeutics

Advancing our novel ADC platform with a new payload class and a new approach to patient selection.

Etienne Dardenne

Etienne Dardenne

New York, New York, United States

Drug discovery and development

Senior Director, Head of Biology at Alphina Therapeutics
(Dec 2025 – Present)

Aabha Sharma

Aabha Sharma

United States

Alphina Corporate Development | ex-L.E.K.

Redefining precision oncology for ADCs with a novel payload

BF

Barbara Fox

Washington, District of Columbia, United States

Biotech Executive, Independent Board Member, Serial Entrepreneur

Independent Board Chair at Alphina Therapeutics
(Oct 2024 – Present)

JK

John Kadow

Wallingford, Connecticut, United States

Sr. VP, Head of Medicinal Chemistry at Alphina Therapeutics: Retired! Currently SAB Member / working part time as consultant for Alphina

(Sr. VP Med Chem: Retired), currently SAB Member / consultant at Alphina Therapeutics
(Jun 2025 – Present)

Search similar profiles
Frequently asked questions about Stanley Choy

What is Stanley Choy email address?

Email Stanley Choy at [email protected] and [email protected]. This email is the most updated Stanley Choy's email found in 2026.

How to contact Stanley Choy?

To contact Stanley Choy send an email to [email protected] or [email protected].

What company does Stanley Choy work for?

Stanley Choy works for Alphina Therapeutics.

What is Stanley Choy's role at Alphina Therapeutics?

Stanley Choy is Chief Financial Officer

What industry does Stanley Choy work in?

Stanley Choy works in the Pharmaceuticals industry.

Find anyone, anywhere
with ContactOut today

Making remote or global hires? Connecting
with key decision-makers? We can help.

  • 40 emails / month
  • 3 phone numbers / month
  • Works on standard LinkedIn only
  • Work emails, personal emails,
    mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free